Series of articles on access to affordable medicines and generics
Can India still supply cheap medicines for the world? By Martin Khor
For millions of poor and sick people around the world, the Indian pharmaceutical industry has been something of a life-saver, thanks to its capacity to produce cheap generic versions of expensive patented drugs. However, some recent developments are threatening to undermine India’s role as the pharmacy of the developing world. Martin Khor explains.
Why generics? By Jayabalan Thambyappa and Mohamed Azmi Ahmad Hassali
There is much confusion and misconception about the nature and efficacy of generic medicines. The following piece seeks to dispel some common myths and fallacies.
An unhealthy future for the Indian pharmaceutical industry? By KM Gopakumar and MR Santhosh
In the following analysis of the Indian pharmaceutical industry, KM Gopakumar and MR Santhosh examine the many challenges facing the industry and the policy options open to the Indian government to avert an impending crisis in its capacity to continue the production of cheap generics.
The EU-India free trade agreement and access to medicines By Kajal Bhardwaj
The free trade agreement which India is negotiating with the European Union threatens to jettison some of the health safeguards in India’s patent legislation which make possible the production of cheap generic medicines. Kajal Bhardwaj identifies the draft treaty provisions which raise serious concern.
‘Protect our medicines, our health, our lives’ By Ranja Sengupta
The EU-India Summit in February touched off protests by health activists and civil society groups both in India and around the world against the free trade agreement currently being negotiated between these parties. Ranja Sengupta reports.
ACTA: undemocratic, dangerous and wrong. By Charlie Harvey
The European Parliament will be voting later this year on an Anti-Counterfeiting Trade Agreement (ACTA) which blurs the distinction between counterfeit and generic medicines by requiring customs officials to treat generic medicines as if they were counterfeit goods and seize them. Despite strong protests by civil society activists, the agreement has already been signed by several EU members and a number of other countries.
The compulsory licence on sorafenib: A right step to ensure access to medicines.By KM Gopakumar
The decision by the Indian Patent Office to grant a local company a compulsory licence to produce a generic version of an anti-cancer drug patented by Bayer on the grounds that it was not available at a ‘reasonably affordable price’ is a major step to ensure access to medicines.
Access the full articles here.